UthPeak™: World’s First Clinical Trial on NMNH

Overview


EFFEPHARM LTD

NMNH, the reduced form of NMN, is a potent NAD+ precursor.

As the world’s first Self-GRAS approved NMNH, UthPeak™ has completed the world’s largest and longest human clinical trial. The results demonstrate UthPeak™ NMNH’s efficacy in several key areas:

  • NAD+ Levels: Increased by 3 times
  • Biological Age: Reduced by an average of 5 years
  • Energy Levels: Enhanced by 35%
  • Emotional Health: Improved by 31%

The Phase II clinical trial will assess UthPeak™ NMNH’s potential for improving sleep quality, cardioprotection, and neuroprotection

This content is provided by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients-USA.com

Download Now


Latest Content

Uthever NMN, effective solution to UV skin damage

Uthever NMN, effective solution to UV skin damage

Paid for and content provided by Effepharm Ltd

Several independent studies have been conducted to understand the relationship between NMN and aging, and to verify the potency of the anti-aging molecule NMN in reversing skin aging caused by UV radiation.

Related Resources

Your Product Innovation Begins Here: Booth 4055

Your Product Innovation Begins Here: Booth 4055

Content provided by Effepharm Ltd

Product Brochure

EffePharm will showcase innovative anti-aging solutions, featuring UthPeak™, world’s first self-GRAS approved NMNH, which boosts NAD+ levels by 10X. UthPeak™ NMNH can be sold, used, and consumed in the U.S. food supply.

UthPeak™ Reduced NMN Is Now Self-GRAS Approved

UthPeak™ Reduced NMN Is Now Self-GRAS Approved

Content provided by Effepharm Ltd

Product Brochure

UthPeak™ NMNH, marketed as "The Next-Gen Super NAD+ Enhancer," is a patent-pending crystalline NMNH that has demonstrated a remarkable 10X surge in NAD+ levels.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.